Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Long who wrote (1883)	8/24/1999 2:29:00 AM
From: Rick Strange	Read Replies (2) \| Respond to of 2205

Bruce, As you know, Dermagraft is grown from cells cultured from donated infant foreskin. That infant was carried by its mother for nine months without rejection even though 50% of its DNA is different. Someone with a better technical background (maybe Marshall) will have to explain the specific mechanism, but tissue from infants doesn't seem to trigger the immune response that causes rejection. ATIS, ORG and ORTC all start with cells from infant foreskin and I don't remember any specific rejection problems with any of these products. The seed cells for ATIS's collagen and cartilage comes from infant cadavers for this same reason.